Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.
Laouénan C, Marcellin P, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Peytavin G, Mentré F, Guedj J. Laouénan C, et al. Among authors: hezode c. Antimicrob Agents Chemother. 2014 Sep;58(9):5332-41. doi: 10.1128/AAC.02611-14. Epub 2014 Jun 30. Antimicrob Agents Chemother. 2014. PMID: 24982076 Free PMC article. Clinical Trial.
Standardization of hepatitis C virus RNA quantification.
Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Pawlotsky JM, et al. Among authors: hezode c. Hepatology. 2000 Sep;32(3):654-9. doi: 10.1053/jhep.2000.16603. Hepatology. 2000. PMID: 10960464 Clinical Trial.
Antiviral action of ribavirin in chronic hepatitis C.
Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L, Dhumeaux D. Pawlotsky JM, et al. Among authors: hezode c. Gastroenterology. 2004 Mar;126(3):703-14. doi: 10.1053/j.gastro.2003.12.002. Gastroenterology. 2004. PMID: 14988824
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.
Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourlière M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, Thiefin G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M, Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrère JJ, Lunel-Fabiani F. Payan C, et al. Among authors: hezode c. J Viral Hepat. 2005 Jul;12(4):405-13. doi: 10.1111/j.1365-2893.2005.00605.x. J Viral Hepat. 2005. PMID: 15985012
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
Bonny C, Fontaine H, Poynard T, Hézode C, Larrey D, Marcellin P, Bourlière M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A. Bonny C, et al. Among authors: hezode c. Aliment Pharmacol Ther. 2006 Aug 15;24(4):593-600. doi: 10.1111/j.1365-2036.2006.03018.x. Aliment Pharmacol Ther. 2006. PMID: 16907892
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM. Bronowicki JP, et al. Among authors: hezode c. Gastroenterology. 2006 Oct;131(4):1040-8. doi: 10.1053/j.gastro.2006.07.022. Epub 2006 Jul 24. Gastroenterology. 2006. PMID: 17030174 Clinical Trial.
Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, Castera L, Bernard PH, Henquell C, Lafeuille H, Ughetto S, Darcha C, Chevallier M, Martineau N, Dubost S, Randl K, Dhumeaux D, Bommelaer G, Bonny C; French multicenter study group. Abergel A, et al. Among authors: hezode c. J Viral Hepat. 2006 Dec;13(12):811-20. doi: 10.1111/j.1365-2893.2006.00768.x. J Viral Hepat. 2006. PMID: 17109680 Clinical Trial.
192 results